166,491 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by Banque Transatlantique SA

Key Points

• Banque Transatlantique SA has acquired a new position in Amicus Therapeutics, Inc., purchasing 166,491 shares valued at approximately $1.26 million, representing a 0.05% ownership stake.
• Wall Street analysts have varied views on Amicus Therapeutics, with Morgan Stanley upgrading its rating to "overweight," while Wall Street Zen downgraded it to "hold," leading to a consensus of eight Buy ratings and two Hold ratings.
• The stock is currently trading at $7.85, with a market cap of $2.42 billion, and a recent analysis indicates an average price target of $16.22 per share.

Banque Transatlantique SA purchased a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 166,491 shares of the biopharmaceutical company's stock, valued at approximately $1,255,000. Banque Transatlantique SA owned approximately 0.05% of Amicus Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC grew its stake in shares of Amicus Therapeutics by 53.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 24,530 shares of the biopharmaceutical company's stock valued at $195,000 after purchasing an additional 8,567 shares during the period. Jefferies Financial Group Inc. acquired a new stake in Amicus Therapeutics in the 1st quarter valued at $1,533,000. Rice Hall James & Associates LLC grew its position in Amicus Therapeutics by 46.6% in the first quarter. Rice Hall James & Associates LLC now owns 2,010,104 shares of the biopharmaceutical company's stock valued at $16,402,000 after acquiring an additional 639,024 shares during the period. Invesco Ltd. raised its stake in Amicus Therapeutics by 4.1% during the first quarter. Invesco Ltd. now owns 2,661,394 shares of the biopharmaceutical company's stock worth $21,717,000 after acquiring an additional 105,856 shares in the last quarter. Finally, Victory Capital Management Inc. raised its stake in Amicus Therapeutics by 47.4% during the first quarter. Victory Capital Management Inc. now owns 257,088 shares of the biopharmaceutical company's stock worth $2,098,000 after acquiring an additional 82,691 shares in the last quarter.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD traded down $0.17 during midday trading on Tuesday, reaching $7.82. The company's stock had a trading volume of 610,382 shares, compared to its average volume of 3,869,705. The business's fifty day simple moving average is $6.79 and its 200-day simple moving average is $7.02. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The company has a market capitalization of $2.41 billion, a P/E ratio of -65.04 and a beta of 0.55.

Analyst Upgrades and Downgrades

FOLD has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $16.00.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.